Trials / Completed
CompletedNCT00724776
Albinterferon Alfa 2b Single Dose in Japanese Chronic Hepatitis C Patients
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Escalating Single Dose of Albinterferon Alfa 2b (Alb-IFN), Recombinant Human Albumin-interferon Alfa Fusion Protein in Japanese Chronic Hepatitis C Patients.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 20 Years – 69 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of albinterferon alfa 2b (alb-IFN) single dose in Japanese chronic hepatitis C patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Albinterferon alfa 2b | recombinant human albumin-interferon alfa fusion protein, 600-1800mcg single dose by S.C. on Day 0 |
Timeline
- Start date
- 2008-07-01
- Primary completion
- 2009-07-01
- First posted
- 2008-07-30
- Last updated
- 2020-12-08
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT00724776. Inclusion in this directory is not an endorsement.